We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$11.5B
1-Year Est. Return
168.77%
This Fund
S&P 500
This Quarter
Est. Return
-17.8%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$4.58B
AUM Growth
-$1.09B
(-19%)
Cap. Flow
+$290M
Cap. Flow
% of AUM
6.34%
Top 10 Holdings %
Top 10 Hldgs %
44.83%
Holding
107
New
10
Increased
11
Reduced
7
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$158M |
| 2 |
Natera
NTRA
|
+$78.7M |
| 3 |
Enanta Pharmaceuticals
ENTA
|
+$62.7M |
| 4 |
AN2 Therapeutics
ANTX
|
+$55.6M |
| 5 |
Cytek Biosciences
CTKB
|
+$51M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novavax
NVAX
|
+$125M |
| 2 |
Phathom Pharmaceuticals
PHAT
|
+$61.3M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$54.2M |
| 4 |
C4 Therapeutics
CCCC
|
+$44.4M |
| 5 |
TG Therapeutics
TGTX
|
+$42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.82% |
| 2 | Financials | 0.96% |
| 3 | Miscellaneous | 0.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
MacroGenics
MGNX
$257M
| $53.8M | 1.17% |
6,103,594
| – | – |
|
|
27
Natera
NTRA
$50.6B
| $53.3M | 1.16% |
+1,310,289
| New | +$78.7M |
|
28
Instil Bio
TIL
$48.9M
| $52.4M | 1.14% |
243,540
| – | – |
|
|
29
Novavax
NVAX
$1.52B
| $51M | 1.11% |
692,794
-1,405,000
| -67% | -$125M |
|
|
KNTE
30
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $48M | 1.05% |
4,264,144
+671,092
| +19% | +$7.39M |
|
31
Vera Therapeutics
VERA
$2.43B
| $46.2M | 1.01% |
+1,966,084
| New | +$42.3M |
|
|
PRDS
32
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $44.6M | 0.97% |
6,175,038
+3,048,000
| +97% | +$30M |
|
|
ICVX
33
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $42M | 0.92% |
5,963,565
+184,218
| +3% | +$2.9M |
|
34
Tenaya Therapeutics
TNYA
$150M
| $41.8M | 0.91% |
3,551,508
| – | – |
|
35
Geron
GERN
$842M
| $41M | 0.89% |
30,126,299
| – | – |
|
36
EyePoint Inc
EYPT
$316M
| $41M | 0.89% |
3,370,506
| – | – |
|
|
RNAM
37
DELISTED
Avidity Biosciences
RNAM
| $40M | 0.87% |
2,167,391
+1,743,775
| +412% | +$29.6M |
|
38
Acumen Pharmaceuticals
ABOS
$209M
| $38.2M | 0.83% |
9,770,773
| – | – |
|
39
RxSight
RXST
$234M
| $37.8M | 0.82% |
3,052,796
| – | – |
|
40
PMV Pharmaceuticals
PMVP
$72.7M
| $35.6M | 0.78% |
1,710,265
| – | – |
|
41
Design Therapeutics
DSGN
$765M
| $35.3M | 0.77% |
2,186,636
| – | – |
|
42
Rocket Pharmaceuticals
RCKT
$374M
| $33.4M | 0.73% |
2,107,149
| – | – |
|
|
CNTA
43
DELISTED
Centessa Pharmaceuticals
CNTA
| $32.1M | 0.7% |
3,577,094
| – | – |
|
44
Guardant Health
GH
$23.6B
| $31.6M | 0.69% |
+476,380
| New | +$32.6M |
|
45
Aclaris Therapeutics
ACRS
$814M
| $31.3M | 0.68% |
+1,817,808
| New | +$24.8M |
|
|
CCXI
46
DELISTED
ChemoCentryx, Inc.
CCXI
| $29M | 0.63% |
+1,155,964
| New | +$32.5M |
|
|
KALV
47
DELISTED
KalVista Pharmaceuticals
KALV
| $28.5M | 0.62% |
1,930,322
| – | – |
|
|
LIAN
48
DELISTED
LianBio American Depositary Shares
LIAN
| $28.4M | 0.62% |
7,655,015
| – | – |
|
49
Dyne Therapeutics
DYN
$3.34B
| $27M | 0.59% |
2,805,045
| – | – |
|
|
VRNA
50
DELISTED
Verona Pharma
VRNA
| $25.4M | 0.56% |
5,100,000
| – | – |
|
Similar funds
AAIS
MG
CC
AI
BMSSC
HTC
WAM
RA Capital Management's Q1 2022 Portfolio in Review
As of Q1 2022, RA Capital Management held 107 positions worth $4.58B, down 19% from $5.67B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
RA Capital Management deployed $290M of net new capital in Q1 2022, opening 10 new positions and adding to 11 existing holdings. Its largest new stake was Biogen: 727,024 shares worth $153M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Miscellaneous.
On the sell side, the largest reduction was Novavax, an estimated $125M trimmed.
- RA Capital Management's largest Q1 2022 buy was Biogen: 727,024 shares worth $153M.
- RA Capital Management added most to Cytek Biosciences in Q1 2022, an estimated $51M increase.
- RA Capital Management's biggest Q1 2022 reduction was Novavax, cutting an estimated $125M.
- RA Capital Management fully exited Phathom Pharmaceuticals in Q1 2022, selling an estimated $61.3M.
- RA Capital Management's ten largest holdings make up 45% of its $4.58B portfolio in Q1 2022.
- RA Capital Management opened 10 new positions and closed 11 in Q1 2022.
- RA Capital Management's portfolio value fell 19% quarter-over-quarter to $4.58B.
Based on RA Capital Management's 13F filing for Q1 2022, filed 16 May 2022.